FindTrial
Sign In

Machine learning-based imageomics in esophageal squamous cell carcinoma who underwent neoadjuvant immunotherapy followed by surgery: Predicting the overall survival

Machine learning-based imageomics in esophageal squamous cell carcinoma who underwent neoadjuvant immunotherapy followed by surgery: Predicting the overall survival

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300068082
Enrollment
Unknown
Registered
2023-02-06
Start date
2023-02-06
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer

Interventions

Group of esophageal cancer:None

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with esophageal cancer who underwent esophageal cancer resection after neoadjuvant immunotherapy and underwent second-field or third-field lymph node dissection; 2. Patients with pathologically confirmed squamous cell carcinoma of the esophagus; 3. The age is between 18-80 years old; 4. The pathological stage is pT1-pT2.

Exclusion criteria

Exclusion criteria: 1.The tumor is located at the gastroesophageal junction; 2. Esophageal squamous cell carcinoma patients with distant metastasis; 3. Patients with a history of other malignant tumors; 4. Patients aged 80 years old; 5. Patients whose lesions are too small to be recognized by CT.

Design outcomes

Primary

MeasureTime frame
Imageomic features;Overall survival;—

Secondary

MeasureTime frame
Disease-free survival;—

Countries

China

Contacts

Public ContactLongqi Cheng

West China Hospital of Sichuan University

drchenlq@scu.edu.cn+86 18980601850

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026